Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 807 of 6351
-
Radioactive drug takes on standard therapy for rare lung and thymus cancers
Disease control Recruiting nowLEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly incre…
Phase 3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a hot bath after exercise help heal the heart?
Disease control OngoingMyocardial infarction (MI) is a leading cause of death in developed countries, including Sweden. Standard treatment for patients after MI includes exercise-based cardiac rehabilitation which contributes to improved cardiovascular function and reduces the risk of hospital readmiss…
Sponsor: Region Örebro County • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to reduce bulging eyes in thyroid disease
Disease control CompletedThe purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Routine heart scans after stents: could they save lives?
Knowledge-focused Recruiting nowComparison of clinical outcomes between routine angiography follow-up and routine clinical follow-up after percutaneous coronary intervention in high-risk patients.
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can steroids save lives during IPF Flare-Ups? new trial aims to find out
Disease control Recruiting nowAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed…
Phase 3 • Sponsor: Fondation Hôpital Saint-Joseph • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Double-targeted cell therapy takes on hard-to-treat lymphomas
Disease control Recruiting nowThis research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Flu…
Phase 1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can connecting the body to the earth help cancer patients sleep?
Symptom relief CompletedSleep disturbance is one of the most common and most persistent symptoms in patients admitted for cancer care, and the options available during a short hospital stay are limited. The human body is electrically conductive, so an alternating potential - known as body voltage - is i…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
New hope for lung scarring: phase 3 trial underway
Disease control OngoingThe purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against rare sarcomas
Disease control OngoingThis phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the bod…
Phase 2 • Sponsor: National Cancer Institute LAO • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingA Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a common cancer drug help rare tumors? new trial aims to find out
Disease control Recruiting nowThis clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer, hepatocellular carcinoma and triple negative breast …
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Diabetes drug could help heart failure patients with leaky valve
Disease control OngoingThe Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation (EVENT) was designed to examine the hypothesis that, compared with placebo, therapy with the SGLT2 inhibitor enavogliflozin would improve clinical and echocardiographic outcomes in heart failure (HF) patients …
Phase 3 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immune cells supercharged to fight advanced cancers
Disease control Recruiting nowThis is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Phase 1/2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Brain scans may replace invasive electrodes for epilepsy surgery planning
Knowledge-focused Recruiting nowThe goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient. The investigators aim to compare epileptogenic network identification with stereo-EEG (used as glod standard) with the identification of the s…
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New One-Time procedure aims to prevent dangerous aneurysm growth
Disease control Recruiting nowThe purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demon…
Phase 2/3 • Sponsor: Nectero Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a diabetes drug shield kidneys from autoimmune attack?
Disease control Recruiting nowThe RENATO trial is a multicenter randomized controlled trial that evaluates the efficacy of pioglitazone to improve renal outcomes in ANCA-associated vasculitis. Patients with biopsy-proven kidney involvement of ANCA vasculitis will be included in this trial at diagnosis. All p…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New study tracks how a targeted drug stacks up against chemo for Hard-to-Treat breast cancer
Disease control Recruiting nowTrastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of comple…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for MDS anemia: luspatercept vs standard care in phase 3 trial
Disease control OngoingThe purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New heart procedure could tame irregular heartbeat
Disease control OngoingThis clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™ X EP System EnSite™ Pulsed Field Ablation Module (…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC